Possible Therapeutic Application of Targeting Type II Natural Killer T Cell-Mediated Suppression of Tumor immunity

被引:16
作者
Kato, Shingo [1 ]
Berzofsky, Jay A. [2 ]
Terabe, Masaki [2 ]
机构
[1] Yokohama City Univ, Sch Med, Dept Gastroenterol & Hepatol, Yokohama, Kanagawa, Japan
[2] NCI, Mol Immunogenet & Vaccine Res Sect, Vaccine Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA
来源
FRONTIERS IN IMMUNOLOGY | 2018年 / 9卷
关键词
natural killer T cell; type II natural killer T cell; tumor immunology; immune regulation; immunosuppression; immunotherapy; lipid antigens; transforming growth factor beta; GROWTH-FACTOR-BETA; INVARIANT NKT CELLS; CHRONIC LYMPHOCYTIC-LEUKEMIA; INFLAMMATORY-LIVER-DISEASE; GAUCHER-DISEASE; CD1D EXPRESSION; ADIPOSE-TISSUE; ALPHA-GALACTOSYLCERAMIDE; MONOCLONAL-ANTIBODY; ULCERATIVE-COLITIS;
D O I
10.3389/fimmu.2018.00314
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Natural killer T (NKT) cells are a unique T cell subset that exhibits characteristics from both the innate immune cells and T cells. There are at least two subsets of NKT cells, type I and type II. These two subsets of NKT cells have opposite functions in antitumor immunity. Type I NKT cells usually enhance and type II NKT cells suppress antitumor immunity. In addition, these two subsets of NKT cells cross-regulate each other. In this review, we mainly focus on immunosuppressive NKT cells, type II NKT cells. After summarizing their definition, experimental tools to study them, and subsets of them, we will discuss possible therapeutic applications of type II NKT cell pathway targeted therapies.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Integrative analysis of T cell-mediated tumor killing-related genes reveals KIF11 as a novel therapeutic target in esophageal squamous cell carcinoma
    Cheng, Xinxin
    Zhao, Huihui
    Li, Zhangwang
    Yan, Liping
    Min, Qingjie
    Wu, Qingnan
    Zhan, Qimin
    JOURNAL OF TRANSLATIONAL MEDICINE, 2025, 23 (01)
  • [42] Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen-Specific T-cell Immunity in Head and Neck Cancer Patients
    Srivastava, Raghvendra M.
    Lee, Steve C.
    Andrade Filho, Pedro A.
    Lord, Christopher A.
    Jie, Hyun-Bae
    Davidson, H. Carter
    Lopez-Albaitero, Andres
    Gibson, Sandra P.
    Gooding, William E.
    Ferrone, Soldano
    Ferris, Robert L.
    CLINICAL CANCER RESEARCH, 2013, 19 (07) : 1858 - 1872
  • [43] Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30
    Kellner, Christian
    Guenther, Andreas
    Humpe, Andreas
    Repp, Roland
    Klausz, Katja
    Derer, Stefanie
    Valerius, Thomas
    Ritgen, Matthias
    Brueggemann, Monika
    van de Winkel, Jan G. J.
    Parren, Paul W. H. I.
    Kneba, Michael
    Gramatzki, Martin
    Peipp, Matthias
    ONCOIMMUNOLOGY, 2016, 5 (01):
  • [44] Dominant negative TGF-β receptor type II in T lymphocytes promotes anti-tumor immunity by modulating T cell subsets and enhancing CTL responses
    Li, Hao
    Guan, Yanling
    Han, Chenchen
    Zhang, Yu
    Chen, Yizhao
    Jiang, Liping
    Zhang, Pingping
    Chen, Xiu
    Wei, Wei
    Ma, Yang
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 148
  • [45] Targeting transforming growth factor-β2 by antisense oligodeoxynucleotide accelerates T cell-mediated tumor rejection in a humanized mouse model of triple-negative breast cancer
    Lee, Hong Kyu
    Ji, Hyeong-Jin
    Shin, Sang-Kyung
    Koo, Jihye
    Kim, Tae Hun
    Kim, Cho-Won
    Seong, Yeon Hee
    Park, Jun-Eui
    Choi, Kyung-Chul
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (09) : 2213 - 2226
  • [46] A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®
    Betts, Alison
    Haddish-Berhane, Nahor
    Shah, Dhaval K.
    van der Graaf, Piet H.
    Barletta, Frank
    King, Lindsay
    Clark, Tracey
    Kamperschroer, Cris
    Root, Adam
    Hooper, Andrea
    Chen, Xiaoying
    AAPS JOURNAL, 2019, 21 (04)
  • [47] A Translational Quantitative Systems Pharmacology Model for CD3 Bispecific Molecules: Application to Quantify T Cell-Mediated Tumor Cell Killing by P-Cadherin LP DART®
    Alison Betts
    Nahor Haddish-Berhane
    Dhaval K. Shah
    Piet H. van der Graaf
    Frank Barletta
    Lindsay King
    Tracey Clark
    Cris Kamperschroer
    Adam Root
    Andrea Hooper
    Xiaoying Chen
    The AAPS Journal, 21
  • [48] A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8+ T-cell-mediated anti-tumor immunity
    Song, Ying-Chyi
    Cheng, Han-Yin
    Leng, Chih-Hsiang
    Chiang, Sheng-Kuo
    Lin, Chih-Wei
    Chong, Pele
    Huang, Ming-Hsi
    Liu, Shih-Jen
    JOURNAL OF CONTROLLED RELEASE, 2014, 173 : 158 - 165
  • [49] Effects of perioperative immunonutrition on cell-mediated immunity, T helper type 1 (Th1)/Th2 differentiation, and Th17 response after pancreaticoduodenectomy
    Suzuki, Daisuke
    Furukawa, Katsunori
    Kimura, Fumio
    Shimizu, Hiroaki
    Yoshidome, Hiroyuki
    Ohtsuka, Masayuki
    Kato, Atsushi
    Yoshitomi, Hideyuki
    Miyazaki, Masaru
    SURGERY, 2010, 148 (03) : 573 - 581
  • [50] Targeting MMP9 in CTNNB1 mutant hepatocellular carcinoma restores CD8+ T cell-mediated antitumour immunity and improves anti-PD-1 efficacy
    Cai, Ning
    Cheng, Kun
    Ma, Yue
    Liu, Sha
    Tao, Ran
    Li, Yani
    Li, Danfeng
    Guo, Bin
    Jia, Wenlong
    Liang, Huifang
    Zhao, Jianping
    Xia, Limin
    Ding, Ze-yang
    Chen, Jinhong
    Zhang, Wanguang
    GUT, 2024, 73 (06) : 985 - 999